News from Annual Meeting: Could Some Patients Stop Taking Medication for CML?

patientpower has 2403 videos Subscribe Here

Description: Jeffrey Lipton discusses news from ASCO 2012 about how Tasigna could bring faster and deeper responses, taking some newly diagnosed patients all the way to Complete Molecular Response (CMR) well within the first year of therapy. Dr. Lipton explains that the focus in Chronic Myelogenous Leukemia (CML) is moving away from simply keeping patients alive and toward the possibility of a cure and being able to discontinue treatment.
Shared By : patientpower
Posted on : 07/09/12
Added : 5 years ago
Category : News